Mark Froimson - 10 Jun 2026 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Reporting relationship: Director
Issuer ticker: PCRX
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 21:06:59 UTC
Prior SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Kristen Williams, Attorney-in-Fact

Key filing fact

Mark Froimson filed Form 4 for Pacira BioSciences, Inc. (PCRX) on 12 Jun 2026.

Key facts

This page summarizes Mark Froimson's Form 4 filing for Pacira BioSciences, Inc. (PCRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 21:06.

Change

Previous filing in this sequence was filed on 19 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001709050 Primary reporting owner

Froimson Mark

Relationship: Director
Address: C/O PACIRA BIOSCIENCES, INC., 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE
Signature: /s/ Kristen Williams, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCRX transaction

Common Stock

Award

Transaction value
Shares: +6,405
Change %: +32%
Price: $0.000000^*
Shares after: 26,541
Date: 10 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +10,891
Change %
Price: $0.000000^*
Shares after: 10,891
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,891
Exercise price: $23.42
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Footnote F2

The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.